



MATERIAL SAFETY DATA SHEET

Revision date: 06-May-2011

Version: 1.0

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
ChemSafe (24 hours): +44 (0)208 762 8322

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Lorazepam Tablets

Trade Name:	ATIVAN
Chemical Family:	Benzodiazepine
Intended Use:	Pharmaceutical product used as antianxiety agent

2. HAZARDS IDENTIFICATION

Appearance: White crystalline powder
Signal Word: WARNING

Statement of Hazard: Suspected of damaging the unborn child.
May cause harm to breastfed babies.

Additional Hazard Information:
Known Clinical Effects: Adverse effects most commonly reported in clinical use include sedation, dizziness, weakness, clumsy motion of limbs/trunk (ataxia), incoordination, fatigue, drowsiness, amnesia, confusion, state of intense good feeling (euphoria), suicidal behavior. Benzodiazepines may cause fetal damage when administered during pregnancy. Secreted in human breast milk.

EU Indication of danger: Toxic to Reproduction: Category 2

EU Hazard Symbols:



EU Risk Phrases:

R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.
Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 2 of 7
Version: 1.0

2. HAZARDS IDENTIFICATION

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Lorazepam	846-49-1	212-687-6	R64 Repr. Cat.2;R61	1-2
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Lactose hydrous	64044-51-5	Not Listed	Not Listed	*
Polacrillin potassium	39394-76-8	Not Listed	Not Listed	*

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.
- Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

- Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.
- Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride and other chlorine-containing compounds.
- Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
- Fire / Explosion Hazards:** High sensitivity of a dust cloud to ignition, based on minimum ignition energy. Strong dust explosion characteristic.

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 3 of 7
Version: 1.0

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of the spill if it is safe to do so. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids, due to the potential for electrostatic discharge and the strong dust explosion characteristic and high sensitivity to ignition.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³ TWA
Australia TWA	10 mg/m ³
Belgium OEL - TWA	Listed
Estonia OEL - TWA	Listed
France OEL - TWA	Listed
Ireland OEL - TWAs	Listed
Latvia OEL - TWA	Listed
OSHA - Final PELs - TWAs:	15 mg/m ³ total 5 mg/m ³
Portugal OEL - TWA	Listed
Romania OEL - TWA	Listed
Spain OEL - TWA	Listed

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³ TWA
Australia TWA	10 mg/m ³
Belgium OEL - TWA	Listed
Ireland OEL - TWAs	Listed
Lithuania OEL - TWA	Listed
Portugal OEL - TWA	Listed
Spain OEL - TWA	Listed
Sweden OEL - TWAs	Listed

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 4 of 7
Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Lorazepam

Pfizer Occupational Exposure Band (OEB): OEB 4 (control exposure to the range of >1ug/m³ to <10ug/m³)

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Dust Explosivity:
Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Chemical Stability: Stable at normal conditions
Conditions to Avoid: Keep away from heat and other sources of ignition, including electrostatic discharge.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Lorazepam

Mouse Oral LD50 1850 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m³

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 5 of 7
Version: 1.0

11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg

Rabbit Dermal LD50 > 2000 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating

Eye Irritation Rabbit Non-irritating

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Lorazepam

Fertility and Embryonic Development Rabbit Intravenous 40 mg/kg/day LOAEL Fetotoxicity

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Lorazepam

18 Month(s) Rat Oral Not carcinogenic

18 Month(s) Mouse Oral Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 6 of 7
Version: 1.0

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Toxic to Reproduction: Category 2

EU Risk Phrases:
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

EU Safety Phrases:
S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.
S45 - In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
WARNING
Suspected of damaging the unborn child.
May cause harm to breastfed babies.

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a very toxic materials



Lorazepam

California Proposition 65	developmental toxicity, initial date 7/1/90
U.S. Drug Enforcement Administration:	Schedule IV Controlled Substance
Australia (AICS):	Listed
EU EINECS/ELINCS List	212-687-6

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	232-674-9

Lactose hydrous

Australia (AICS):	Listed
--------------------------	--------

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)	Listed
Australia (AICS):	Listed
EU EINECS/ELINCS List	209-150-3

Additional Information: US DEA Schedule IV substance

MATERIAL SAFETY DATA SHEET

Material Name: Lorazepam Tablets
Revision date: 06-May-2011

Page 7 of 7
Version: 1.0

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

R61 - May cause harm to the unborn child.

R64 - May cause harm to breastfed babies.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Prepared by: Product Stewardship Hazard Communications
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet